Residential
Khan, Mohammad
Khan, Mohammad was paid $669K by Medicaid between Jan 2018 and Nov 2024, across 34 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 45% of everything it billed.
33Billing provider infoKHAN, MOHAMMAD
NEWARK, DE 19702
NEWARK, DE 19702
33aNPI1639113285assigned 06/15/2006
33bProvider typeSubstance Abuse Rehabilitation Facility
28Total paid$669K
24GClaims29,692
24DCodes billed34
24AFirst – last monthJan 2018 – Nov 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 877 | $1K | |
| 2019 | 1,008 | $4K | |
| 2020 | 2,773 | $48K | |
| 2021 | 5,932 | $130K | |
| 2022 | 6,499 | $209K | |
| 2023 | 8,577 | $186K | |
| 2024incomplete | 4,026 | $91K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 45% | 4,583 | 3,509 | $301K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 12% | 1,001 | 769 | $79K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 11% | 867 | 721 | $74K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 6.8% | 532 | 451 | $46K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.7% | 363 | 314 | $31K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 3.2% | 2,596 | 2,146 | $21K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 3.0% | 1,274 | 850 | $20K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 2.4% | 481 | 396 | $16K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 2.2% | 2,062 | 1,652 | $15K |
| 90670 | 1.4% | 536 | 435 | $10K | |
| 94760 | 1.2% | 7,218 | 5,513 | $8K | |
| 90686 | 1.0% | 442 | 358 | $7K |
22 more codes
| 90697 | <1% | 236 | $6K | |
| 92551 | <1% | 725 | $5K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 604 | $5K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 70 | $5K |
| 90680 | <1% | 244 | $4K | |
| 86580 | <1% | 685 | $3K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 136 | $2K |
| 90633 | <1% | 168 | $2K | |
| 99173 | <1% | 882 | $2K | |
| 90685 | <1% | 94 | $2K | |
| 90710 | <1% | 78 | $1K | |
| 90651 | <1% | 87 | $1K | |
| 90656 | <1% | 32 | $704.74 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 67 | $677.88 |
| 90696 | <1% | 37 | $526.97 | |
| 0071A | <1% | 19 | $520.00 | |
| 87807 | <1% | 48 | $494.15 | |
| 90698 | <1% | 12 | $254.87 | |
| 90480 | <1% | 20 | $244.00 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 3,417 | $60.00 |
| 91307 | <1% | 24 | $0.02 | |
| D1206 | Topical application of fluoride varnish | 0% | 52 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.